April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.
Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.
Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.
TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
New for the week ending March 15: Study of young black MSM finds no link between PrEP uptake and STI incidence; HIV risk scores and PrEP usage; impact of youth-tailored HIV services; long-acting antiretroviral interest among younger people with HIV.
The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.
Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.